HighTide Therapeutics, Inc. (HKG:2511)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.600
+0.020 (0.78%)
Feb 13, 2026, 4:08 PM HKT
Market Cap1.49B +142.5%
Revenue (ttm)n/a
Net Income-319.05M
EPS-0.71
Shares Out571.33M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume484,000
Average Volume395,538
Open2.580
Previous Close2.580
Day's Range2.500 - 2.600
52-Week Range0.990 - 4.700
Beta0.52
RSI38.28
Earnings DateMar 27, 2026

About HighTide Therapeutics

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies to treat patients with chronic metabolic and liver diseases in Mainland China. Its lead drug candidate is HTD1801, which is in phase III clinical trial to treat type 2 diabetes mellitus (T2DM); in phase IIb clinical trial to treat metabolic dysfunction-associated steatohepatitis (MASH); in phase II clinical trial to treat severe hypertriglyceridemia; and in phase II clinical trial to treat primary sclerosing cholangitis, as well as i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 57
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2511
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements